Myelitis following nCOV-19 vaccine

 

Longitudinal extensive transverse myelitis following ChAdOx1 nCOV-19 vaccine: a case report

• Wee Yong Tan, 
• Abdul Hanif Khan Yusof Khan, 
• Mohd Naim Mohd Yaakob, 
• Anna Misyail Abdul Rashid, 
• Wei Chao Loh, 
• Janudin Baharin, 
• Azliza Ibrahim, 
• Mohd Redzuan Ismail, 
• Liyana Najwa Inche Mat, 
• Wan Aliaa Wan Sulaiman, 
• Hamidon Basri & 
• Fan Kee Hoo 
• • 
    

  • • Abstract

      Background

      Transverse myelitis (TM) is a relatively uncommon condition, and vaccine-associated myelitis is even rarer. Concern regarding neurological complications following vaccination escalated following the report of TM during the safety and efficacy trials of the COVID-19 vaccine.

      Case presentation

      We report the first case of Longitudinal Extensive Transverse Myelitis (LETM) in Malaysia following administration of the chimpanzee adenovirus-vectored (ChAdOx1 nCoV-19) vaccine. A 25-year-old female presented with bilateral lower limb weakness and inability to walk with a sensory level up to T8 with absent visual symptoms. Urgent gadolinium-enhanced magnetic resonance imaging (MRI) of the spine showed long segment TM over the thoracic region. Cerebrospinal fluid autoantibodies for anti-aquaporin-4 and anti-myelin-oligodendrocyte were negative. A diagnosis of LETM following vaccination was made, and the patient was started on a high dose of intravenous methylprednisolone. The patient eventually made a recovery following treatment.

      Conclusion

      LETM is a rare but serious adverse reaction following vaccination. Previously reported cases showed an onset of symptoms between 10 to 14 days post-vaccination, suggesting a delayed immunogenic reaction. However, the incidence of myelitis in COVID-19 is much more common, far greater than the risk associated with vaccination.

    • 
      

    • READ HERE: https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-021-02427-x